Vorinostat

• 产品号: S1047
• CAS号: 149647-78-9
• 分子式: C14H20N2O3
• 分子量: 264.3202
• 保 存: -20°C

产品别名

• 标题: Vorinostat
• IUPAC标准名: N-hydroxy-N'-phenyloctanediamide
• IUPAC传统名: vorinostat
• 别名: SAHA; Zolinza; MK-0683

产品登记号

• CAS号: 149647-78-9

产品性质

• 作用靶点: HDAC
• 成盐信息: Free Base
• 溶解度: DMSO
• 保存条件: -20°C

产品详细信息

详细说明 (English)

Research Area

• Description: Myelodysplastic syndromes, Mesothelioma,Cancer

Protocol

• Protocol: Kinase Assay ^[1]
• Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ^3H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [^3H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
• Protocol: Cell Assay ^[2]
• Cell Lines: LNCaP, PC-3, and TSU-Pr1
• Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM
• Incubation Time: 1, 2, 3 and 4 days
• Methods:

  Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion.

• Protocol: Animal Study ^[2]
• Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells
• Formulation: Dissolved in DMSO
• Doses: ~100 mg/kg/day
• Administration: Injection i.p.

References

• References: [1] Richon VM, et al. Proc Natl Acad Sci U S A, 1998, 95(6), 3003-3007.
• References: [2] Butler LM, et al. Cancer Res, 2000, 60(18), 5165-5170.
• References: [3] Munster PN, et al. Cancer Res, 2001, 61(23), 8492-8497.
• References: [4] Hockly E, et al. Natl Acad Sci U S A, 2003, 100(4), 2041-2046.
• References: [5] Mitsiades CS, et al. Proc Natl Acad Sci U S A, 2004, 101(2), 540-545.

参考文献

• Mitsiades CS, et al. Proc Natl Acad Sci U S A, 2004, 101(2), 540-545.
• Richon VM, et al. Proc Natl Acad Sci U S A, 1998, 95(6), 3003-3007.
• Butler LM, et al. Cancer Res, 2000, 60(18), 5165-5170.
• Munster PN, et al. Cancer Res, 2001, 61(23), 8492-8497.
• Hockly E, et al. Natl Acad Sci U S A, 2003, 100(4), 2041-2046.